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DE F I N I T I O N S  
A major cause of transplant rejection is the activation of T lymphocytes. The antigens 
mainly responsible for this activation are found on cells of the graft and variously 
termed allogeneic MHC molecules, allo-MHC-molecules, or alloantigens. The immune 
response triggered by an allogeneic organ, i.e. an organ from an unrelated donor, is 
an alloimmune response. It can be divided into three phases (Fig. 1). 
 
FIGURE 1: THE THREE PHASES OF THE 
ALLO RESPONSE. In phase 3, the effector 
phase, rejection leads to destruction of 
graft cells by cells of both the acquired 
and innate immune systems (regarding 
phases 1 and 2 see also Fig. 2). 
 
 
Host T lymphocytes recognized by 
alloantigens are termed alloreactive T 
lymphocytes. There are two distinct 
pathways of alloantigen recogni-
tion: (1) The direct pathway, where 
alloreactive T lymphocytes recognize the 
allo-MHC-molecules on the surfaces of the passenger leukocytes transferred with the 
graft and are directly activated by them if they receive the necessary costimulatory 
signals. (2) The indirect pathway, where allogeneic MHC-molecules are processed by 
antigen presenting cells (APC) of the host and presented as allo-MHC-peptides in 
self-MHC-class-II molecules. This pathway was first described in 1982 by Lechler et 
al. (J Exp Med 1982; 155: 31).  
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FIGURE 2: OVERVIEW OF THE CELLULAR MECHANISMS LEADING TO REJECTION. The figure 
highlights the three major components of the alloimmune response: (1) alloantigens, 
the main triggers of the alloimmune response; they can be either MHC-class-I or 
class-II molecules. (2) Alloreactive CD4+ helper T lymphocytes (termed CD4+ T 
lymphocytes in the following), which are activated following alloantigen recognition. 
(3) Cells of the effector phase, which are activated by the alloreactive CD4+ T 
lymphocytes. These include cells of the adaptive immune system, B-lymphocytes, 
and cytotoxic CD8+ T lymphocytes (termed CD8+ T lymphocytes in the following), as 
well as cells of the non-adaptive immune system, such as macrophages and natural 
killer (NK)-cells. The effector phase is characterized by progressive cell destruction 
leading to the loss of graft function [1]. The mechanisms of direct and indirect 
alloantigen recognition are shown in Figs. 2.2 and 2.3. 
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1.  SU M M A R Y 
Transplant rejection is an immune response predominantly mediated by T 
lymphocytes. It is based on the immune system’s ability to distinguish between "self" 
and "nonself". The main stimuli are the highly polymorphic allo-MHC-molecules 
coded by the major histocompatibility complex (MHC) and the allo-MHC-peptides 
processed from such allo-MHC-molecules by antigen presenting cells. 
 
The immunosuppression concept is based on the targeted suppression of the host 
immune system. At present so-called immunosuppressive agents are used to inhibit 
graft rejection. This is not however without risk for patients, since long term 
suppression of the immune system increases the susceptibility to infections and 
malignant diseases. These drawbacks underscore the need for immunomodulating 
approaches that allow antigen-specific suppression of the alloimmune response 
without impairing the immune protection necessary for life. Two specific therapeutic 
concepts described here as ideal therapy based (1) on the modulation of the immune 
response with allo-MHC peptide variants and (2) regulatory CD4+ T lymphocytes. 
  
The effects such allo-MHC peptides have on the host immune system can be 
analyzed in detail because they can be produced synthetically. Studies have shown 
that allo-MHC-peptides possess both immunostimulatory and inhibiting properties. 
Our own data indicate they have a synergistic effect on immunosuppressive agents. 
In animal models preoperative sensitizing of the prospective host with the 
immunostimulatory peptide RT1.B2 in combination with short-term immuno-
suppression was shown to prolong graft function to between 65 and 100 days. This 
phenomenon is known as "linked unresponsiveness" and cannot be achieved when 
each substance is given alone.  
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It is not at present possible to predict under which conditions the inhibiting 
properties of such peptides take effect. The amino acid sequences of allo-MHC-
peptides are therefore purposely changed so as to modulate the properties of 
alloreactive T lymphocytes.  
 
Unlike autoimmune diseases, the alloimmune response does not appear to be based 
on individual peptide antigens. To investigate which allo-MHC-peptide antigens 
dominate in the alloimmune response, we examined seven different peptides that are 
identical to certain areas of the MHC-class-I-molecule of haplotype RT1u (the 
haplotype of the Wistar-Furth [WF] rat), in Lewis (LEW)-rats with the haplotype RT1l 
were tested for their ability to trigger an immune response. These MHC-class-I-
peptides represent the area in the RT1.Au molecule that differs from the RT1.Al 
molecule, i.e. the amino acids found here are different and must be responsible for 
the alloreactivity.  
 
Of the seven allo-MHC-class-I-peptides investigated, the P1 peptide induced an 
immunodominant T-cell response leading to graft rejection. This important finding 
appears to reduce to a few the number of candidate allo-MHC-peptide antigens. In 
order to produce variants of the immunodominant P1 peptide, the three amino acids 
in the MHC-class-I-molecules of WF were sequentially replaced by the three amino 
acids occupying the same position in the MHC-class-I-molecule of LEW rat. With A1.5 
a promising peptide variant was identified that delays graft rejection in an antigen-
specific manner. The effective mechanism of A1.5 has been studied in detail: It 
displaces the original P1 peptide from the binding groove of MHC-class-II molecules. 
 
A further attractive application of allo-MHC-peptides and/or their variants is the 
generation of regulatory cells. Regulatory T lymphocytes are promising mediators of 
peripheral tolerance. They or their secreted interleukins should make it possible to 
demonstrate changes in the immunological situation following transplantation. 
Reliable molecular-immunological markers of graft tolerance would be of great 
importance in clinical practice, since current assays do not always deliver unequivocal 
results.  
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The effect of a limited alloimmune response on the generation of regulatory cells was 
studied in immunologically active liver grafts. The liver actively modulates the 
immune system and after transplantation induces its own acceptance. If subjected to 
antigen stimulus, CD4+ CD45RCneg hepatic T lymphocytes isolated from tolerated liver 
grafts produce the immunoregulatory Th2 interleukin (IL)-13. Another hepatic CD4+ 
T-lymphocyte subpopulation of CD45RCpos phenotype lacks this property, as do CD4+ 
CD45RCneg T lymphocytes of the spleen. Although no data are yet available on the 
immunomodulating effect of IL-13 in liver transplants, demonstration of this cytokine 
in combination with the relevant hepatic T-cell population can serve as a marker of 
stable tolerance. 
 
At present clinical organ transplantation is the sole therapy for irreversibly damaged 
organs. While its success is due in large part to clinical application of the 
immunosuppression concept, its potentially grave side effects underscore the need 
for new strategies. The experimental approaches presented here for antigen-specific 
immunomodulation with allo-MHC-peptides and regulatory T lymphocytes could 
contribute to the development of both new diagnostic concepts and an ideal therapy.  
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2.  IN T R O D U C T I O N 
Organ transplantation has developed worldwide into a successful procedure for 
treating patients with irreversibly damaged organs [2]. Although its success can be 
attributed in large part to the optimization of transplantaiton surgery, organ 
preservation and tissue typing, the major part of its success is undoubtedly due to 
effective application of the immunosuppression concept [3, 4].  
 
 
2.1 THE IMMUNOSUPPRESSION CONCEPT AND THE IDEAL THERAPY 
The immunosuppression concept is based on the targeted suppression of the host’s 
immune system. Application of the appropriate immunosppressive agents inhibits the 
immune response triggered by the graft and thus preserves the viability of the graft 
[5]. In the past 40 years the immunosuppression concept has given rise to effective 
therapies that are especially successful at ensuring short-term graft function. In the 
majority of tranplant centers, the current one-year survival rates for kidney, liver, 
lung and pancreas grafts is between 80% and 90% [6].The long-term maintenance 
of organ function, by contrast, remains a major problem that the current 
immunosuppression concept is largely unable to address. The chronic rejection that 
occurs months to years after transplantation1, 2 does not respond to treatment with 
currently available immunosuppressive agents [7, 8, 9]. Moreover, suppress not only 
the graft-induced immune response, but the immune system’s ability to fight 
infection and maignant disorders as well [10, 11]. They also have serious side effects 
such as nephro- and neurotoxicity. Some of them, especially the calcineurin 
inhibitors, are thought to promote chronic rejection [12].  
                                       
1 Gassel HJ, Otto C, Gassel AM. Chronic rejection in the rat liver transplantation model. Graft 2002; 5: 
149-152 
2 Meyer D, Otto C, Gasser M, Heemann U, Ulrichs K, Thiede A. Chronic rejection after rat liver-small 
bowel transplantation. Graft 2002; 5: 135-140 
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While clinical trials are currently examining novel strategies for lessening the side 
effects of immunosuppresive agents [13, 14], the search continues for an ideal 
therapy based on the immunosuppression concept3 (Fig. 2.1). Even though pro-
gressive rejection is a multicellular event [15], the alloreactive CD4+ T lymphocytes 
play a crucial role in the initiation of rejection [16]. An ideal therapy should therefore 
inhibit the graft induced immune response in an antigen-specifc manner, be free of 
side effects, prevent the alloantigen-specific processes leading to chronic rejection 
[17] and promote the cellular and molecular mechanisms leading to tolerance. This 
would attain the holy grail of transplantation research, the induction of graft-specific 
tolerance [18, 19]. Although the specfications of an ideal therapy are very concrete, 
strategies for its attainment are the subject of intense debate.  
 
It is the goal of the present study therefore to further investigate two concepts for 
antigen-specific immunomodulation, one employing allo-MHC-peptide variants, the 
other regulatory CD4+ T lymphocytes (Chapter 2.4).  
                                       
3 Otto C, Timmermann W, Sitaru G, Jost S, Gassel HJ, Ulrichs K. Modulation of T cell reactivity with 
MHC peptides: A strategy for selective inhibition of the T cell response to allografts? 
Transplantationsmedizin 2001; 13: 21-31 
  6
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2.1: THE IMMUNOLOGICAL SITUATION BEFORE AND AFTER TRANSPLANTATION. At 
present the graft-induced immune response is suppressed by general immuno-
suppression. The goal of the ideal therapy is to selectively suppress the immune 
response to the foreign graft without impairing the immune system’s vital ability to 
protect against infection and tumors. The ideal therapy is based on the antigen-
specific suppression of the activation of the CD4+ T lymphocytes participating in graft 
rejection. 
 
 
 
2.2 HISTORY OF THE IMMUNOSUPPRESSION CONCEPT  
Although the conceptional and experimental foundations of organ transplantation 
have their origins in the second half of the 19th century [20], it was not until 
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December 1954 that Murray et al. performed the first successful kidney transplant 
between identical twins [21]. Only when the same team could show that the immune 
barrier can be therapeutically overcome did transplantation become an attractive 
form of therapy [22, 23].  
 
A special milestone in the development of the immunosuppression concept was the 
clinical introduction of cyclosporine A (CsA) (Sandimmun) in 1980, which represen-
ted an unprecedated revolution in organ transplantaiton: Within 10 years the number 
of transplantations performed annually had increased by tenfold and the kidney 
transplantaiton survival rate in the first year after transplantaiton had risen to almost 
80% [24]. CsA, like the bacterial agent tacrolimus (Prograf) introduced in 1984, 
suppresses the activation of NFAT-dependent genes, such as interleukin (IL)-2, and 
thus is already effective in the early phase of T-cell activation [25, 26]. Despite their 
immunosuppressive potency, the use of calcineurin inhibitors is today now 
challenged due to the severity of their side effects [27]. 
 
At present the most successful monoclonal antibody (mAb) in transplantation 
medicine is the anti-IL-2 receptor antibody basiliximab (Simulect). This antibody 
binds with high afinity to the α-chain of IL-2-receptors and thus suppresses IL-2 
binding [28]. The current clinical successs of Simulect are highly promising, but only 
the future will reveal its true strengths and weaknesses [29]. An important finding of 
experiments with mAb is that while they represent a rational and effective 
supplement to immunosuppressive therapy, their use is not unaccompanied by side 
effects [30, 31].  
 
All current efforts are concentrated on optimization of the immunosuppression 
concept to achieve an optimum of immunosuppressive efficacy with a minimum of 
side effects. A lively discussion is ongoing within the transplantation community 
regarding the possibility of individualized immunosuppression aimed at reducing the 
immunosuppressive dose to the necessary minumum [32]. It is agreed within the 
community that new therapeutic approaches are needed for prevention of chronic 
rejection [33, 34].  
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FIGURE 2.2: THE DIRECT PATHWAY OF ALLOANTIGEN RECOGNITION. The so-called 
passenger leukocytes transferred with the organ transplant activate alloreactive CD4+ 
and CD8+ T lymphocytes [35]. The activated CD4+ T lymphocytes induce various 
effector cells participating in the rejection, among them NK cells, macrophages and B 
lymphocytes. This form of T-cell activation, in which up to 10% of the T lymphocytes 
are involved, is responsible for acute rejection. The basis of the indirect pathway of 
alloantigen recognition is the ability of the T-cell receptor to recognize allo-MHC-
molecules as antigens on the cell surface. The colors indicate cells of different MHC-
haplotypes: cells of the allogeneic graft are shown in red, host cells in grey. 
 
 
 
2.3 THE IMMUNOBIOLOGY OF REJECTION 
The antigens responsible for graft rejection are found both on the foreign graft and 
on its so-called passenger leukocytes (Fig. 2.2). Rejection is caused by the genetic 
incompatibility between the donor and host and was first described by Sir Peter 
Medawar in 1944 [36]. The surface proteins, the MHC-molecules, coded by the 
genes of the MHC are the most potent stimulus of the host immune system [37, 38]. 
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The greater the incompatibility between the donor and host MHC proteins, the more 
rapid and intense the graft rejection [39]. Complete MHC-compatibility however does 
not necessarily mean rejection will not occur, since incompatibilities among the so-
called minor MHC antigens [40] can lead to delayed rejection [41].  
 
Upon transplantation, MHC-molecules, whose task is the presentation of foreign and 
self structures in the form of peptides, themselves become antigens. Allo-MHC-
molecules are recognized by alloreactive T lymphocytes as intact molecules on the 
surfaces of passenger leukocytes. This direct pathway of alloantigen recognition 
leads to activation of both CD4+ and CD8+ T lymphocytes (Fig. 2.2). When, 
conversely, allo-MHC-molecules of host APC are processed to allo-MHC-peptides and 
presented in self-MHC-class-II-molecules on the cell surface, alloreactive CD4+ T 
lymphocytes are activated. This pathway, which is limited to CD4+ T lymphocytes, is 
termed the indirect pathway of alloantigen recognition. In both pathways, activated 
CD4+ T lymphocytes secrete various interleukins by which they modulate the effector 
cells participating in graft rejection (Fig. 2.3). 
 
MHC-molecules are subject to antigen processing and presentation, as shown by 
sequence analyses of peptides eluted from their binding grooves. The large majority 
of these peptides derive from self -MHC-molecules [42]. Their presentation increases 
the sensitivity of naive T lymphocytes to foreign antigens [43]. It is very likely 
therefore that allo-MHC-molecules are also processed after transplantation and 
presented as allo-MHC-peptides [44].  
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FIGURE 2.3: THE INDIRECT PATHWAY OF ALLOANTIGEN RECOGNITION. Antigen 
presenting cells (APC) of the host uptake allo-MHC-molecules, process them to allo-
MHC-peptides, then present them in self-MHC-class-II molecules on their surface 
membranes to their own alloreactive CD4+ T lymphocytes [45, 46]. The alloreactive 
CD4+ T lymphocytes recognizing these allo-MHC-peptides are activated and modulate 
via their interleukins the effector cells participating in rejection. This pathway, which 
can also be demonstrated following clinical transplantation [47], appears to be 
mainly responsible for chronic rejection [48]. 
 
 
 
2.4 THE IDEAL THERAPY: IMMUNOMODULATIVE STRATEGIES 
The serious drawbacks to the immunosuppression concept (Chapter 2.1) underscore 
the need to develop antigen-specific strategies. The following two strategies for 
antigenspecific modulation are being investigated:  
(1) Modulation with peptide variants or altered peptide ligands [49]. Here the 
peptide variants prepared from the immunodominant allo-MHC-peptide antigens 
are used to suppress the activation and proliferation of the CD4+ T lymphocytes 
Rejection
Cyto
kine
s
APC
CD4 CD4
Activation
Macrophages
NK cells
B lymphocytes
activated
CD4+ T lymphocyteCD4
T-cell receptor
Interleukin (IL)-2 receptor + IL-2
Self-MHC class II molecule
with allo-MHC peptide
Uptake & Process
of  allo-MHC antigens
allo-MHC molecule
Parenchymal cells of the MHC-disparate allograft
CD8
CD8
CD8
  11
that mediate rejection and/or to promote effector functions such as the 
production of interleukins so that these cells become effective as regulators [50, 
51, 52, 53]. 
(2) Analysis of the influence of the local alloimmune response on the formation of 
regulatory CD4+ T lymphocytes. These cells are attractive candidates for the 
induction of peripheral tolerance. In this connection, the cytokine profile of 
hepatic CD4+ T lymphocytes following liver transplantation was analyzed for 
signs of an organ-specific regulator cell population. The liver graft in particular is 
known to possess unique immunomodulating properties.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2.4: POSSIBLE ELEMENTS OF THE IDEAL THERAPY. In addition to allo-MHC-
peptides, especially allo-MHC-peptide variants, a hepatic CD4+ T-cell population was 
analyzed for its ability to suppress graft rejection. This cell population, possibly 
responsible for spontaneous tolerance of liver transplants, could form a basis for the 
ideal therapy. 
 
 
 
 
 
                                       
4 Gassel HJ, Otto C. Mechanismen der Immuntoleranz nach orthotoper Lebertransplantation. 
Transplant Links 2002; 2: 49-58 
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2.4.1 IMMUNOMODULATION WITH ALLO-MHC-PEPTIDES 
Activation of T lymphocytes requires specific interaction between the αβ T-cell 
receptor and the peptide antigens located in the binding grooves of self-MHC-class-
II-molecules. Through specific modifications, i.e. through the exchange of individual 
amino acids, the generated peptide variants change this interaction and thus the 
activation of T lymphocytes [54], the magnitude of their proliferation and their 
cytokine profile [55, 56]. Even though the MHC-system is highly polymorphic, the 
HLA-system for example is know to have more than 1,200 variants [57], it should not 
be impossible to establish a therapy employing allo-MHC-peptide antigens [58, 59].5 
 
Hypothesis 1: Synthetic, immunogenic allo-MHC-peptides, which are responsible for 
the alloreactivity of a defined donor and recipient combination in certain areas of the 
allo-MHC-molecules (Fig. 3.2), could form the basis for an antigen-specific therapy 
following transplantation. Such variants of immunodominant peptide antigens should 
suppress the activation of alloreactive T lymphocytes and/or modify their cytokine 
profile in the form of an "immune deviation" [60]. 
 
 
2.4.2 IMMUNOMODULATION WITH REGULATORY CD4+ T LYMPHOCYTES  
The recognition of antigens by T lymphocytes generally triggers effective immune 
response. Under certain conditions however this recognition leads to suppression of 
the immune response [61, 62]. Investigations into the induction and maintenance of 
tolerance by regulatory cells are being carried out by among others the team of 
Waldmann et al. [63]. Their published data on a cellular suppressor mechanism 
transferred by T lymphocytes [64] has revived the idea of an active form of tolerance 
induction [65, 66]. Sakaguchi et al. [67] and Groux et al. [68] describe a subtype of 
CD4+ T lymphocytes that suppresses the immune response both in vitro and in vivo 
[69, 70]. Exactly how such cells mediate their regulatory or suppressive properties is 
not yet known [71]. Since certain functional properties of CD4+ T lymphocytes 
correlate with a characteristic cytokine profile [72], the underlying mechanism of 
                                       
5 Timmermann W, Otto C. Chancen durch Vielfalt. Immunmodulation mit HLA-peptidesn. Z 
Gastroenterol 2002; 40: 468 (abstract) 
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regulatory cells can be interpreted as resulting from specific regulatory interleukins 
[73, 74].  
 
In 1969 Calne reported that liver grafts in the large animal model swine were 
sometimes spontaneously accepted (i.e. without immunosuppression) despite a 
complete MHC incompatibly [75]. The cellular and/or molecular bases of this 
spontaneous acceptance of liver grafts are still not fully understood [76]. Various 
strains of inbred rats have proven to be of use in the analysis of this phenomenon 
[77, 78, 79, 80]. Evidence is growing that the immune response triggered by the 
liver graft is modulated by the graft itself [81, 82].  
 
Hypothesis 2:  The cytokine profile of T lymphocytes with protective 
immunoregulatory properties exhibit an elevated expression of certain interleukins, 
including IL-4, IL-10, IL-13 (Th2 cells) [83], and TGF-β (Th3 cells) [84, 85]. The 
spontaneous liver graft tolerance seen in certain rat strains [86] could be based 
on such a regulatory mechanism.  
  14
3 RE S U L T S  &  DI S C U S S I O N 
3.1  THE ALLO-MHC-PEPTIDE-INDUCED IMMUNE RESPONSE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.1: THE IMMUNOLOGICAL SITUATION FOLLOWING ORGAN TRANSPLANTATION. 
Shown is the relationship between the types and relative strengths of cell activation, 
and the duration of the resulting alloimmune response leading to rejection. 6, 7 Since 
the indirect pathway of alloantigen recognition (Fig. 2.3) is dependent on allo-MHC-
peptides, modified peptide antigens could be exploited to influence both the 
activation and function of alloreactive T lymphocytes. The organ graft and passenger 
leukocytes are shown in red, the host MHC-different immune cells in gray. 
                                       
6 Timm S, Hamelmann W, Otto C, Gassel AM, Etzel M, Ulrichs K, Thiede A, Timmermann W. Influence 
of donor MHC class I antigen expression on graft survival after rat parathyroid 
allotransplantation. Langenbecks Arch Surg 2001; 386: 430-433 
7 Timmermann W, Otto C, Rohde AC, Gasser M, Gassel HJ, Waaga AM, Ulrichs K, Thiede A. Studies 
about immunogenicity and immunomodulation of rat MHC class II peptides in vitro and after 
orthotopic small bowel transplantation. Deutsche Gesellschaft für Chirurgie, Forumband 2000; 
29: 263-265 
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Tolerance, i.e. the immune system’s acquired ability to not react to certain antigens, 
is one of the most impressive phenomena known to immunology [87]. This property 
of the immune system is of crucial importance in the field of transplantation 
medicine. In addition to the central tolerance of the thymus based on clonal deletion, 
the multifarious T lymphocyte reactivity that affects post-thymic processes subsumed 
under the term peripheral tolerance [88]. This includes not only the "frank" 
prevention of T-cell activation, but the modulation of mechanisms affecting 
activation, such as regulatory T lymphocytes. While the current immunosuppression 
concept can be used to treat acute rejection (Chapter 2.1), its approach is too 
nonspecific and its long-term application associated with too many side effects. 
Moreover, continued long-term immunosuppression appears to work against the 
building of tolerance [89, 90]. One possible explanation for this surprising finding is 
that such immunosuppressive agents inhibit expression of the growth factor IL-2, 
which is essential for both the proliferation of alloreactive T lymphocytes and for the 
retention of regulatory T lymphocytes [91].  
 
As mentioned above, the indirect pathway of alloantigen recognition is based on allo-
MHC-peptides (Fig. 2.3). To investigate in detail the effect of such allo-MHC-peptides 
on the immune system, an repertoire of defined peptides is required. To obtain such 
peptides, we began by comparing the amino acid sequences of MHC-molecules of a 
certain combination from the graft donor with those of the recipient. Fig. 3.2 shows 
this comparison of sequences of the MHC-class-I-molecules for the WF and LEW rat 
strains. Peptides of the RT1u locus in the haplotype of the WF rat were synthesized 
from the areas in which the amino acid sequences of the two rat strain haplotypes 
differ and investigated for their possible alloreactivity with the haplotype RT1l of LEW 
rats. The influence of these peptides on graft rejection was analyzed by giving the 
LEW rats heterotopic heart transplants from the WF rats after immunization with 
these RT1u MHC-class-I-peptides (Fig. 3.4). 
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FIGURE 3.2: DEMONSTRATION OF ALLOREACTIVE AREAS IN MHC-CLASS-I-MOLECULES 
OF HAPLOTYPE RT1U AS THE BASIS FOR THE PRODUCTION OF SYNTHETIC ALLO-MHC-
PEPTIDES. We compared the amino acid sequences of the MHC-class-I-molecules of 
the two in-bred rat strains Wistar-Furth (WF) (haplotype RT1u) and Lewis (LEW) 
(haplotype RT1l). The two domains α1 and α2 forming the binding groove of the 
molecule were investigated. The two domains, each comprised of 90 amino acids, 
differ in 17 amino acids between the two haplotypes RT1u and RT1l. The seven RT1u 
peptides, P1 to P7, which cover these areas, were tested in LEW rats for their 
alloreactivity. Two sequences were found to be identical in the area of the peptide 
Pc. Also shown is the distribution of the ß-chains (red arrows) and α-helices (blue 
rectangle) within the two domains [92]. The RT1.Au sequence was published by Joly 
et al. [93], the RT1.Al sequence by Salgar et al. [94].  
 
 
 
The alloreactivity of these peptides, i.e. their ability to activate alloreactive CD4+ T 
lymphocytes, was determined in the assay shown in Fig. 3.3. This assay measures T-
cell proliferation after a second exposure to the peptide antigen. T lymphocytes not 
primed by immunization (= first exposure) were not reactivated in the in vitro assay 
under the described culture conditions.  
α1 domain
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FIGURE 3.3: ASSAY TO MEASURE ALLO-MHC-PEPTIDE-INDUCED T-CELL PROLIFERA-
TION. In a first step RT1u peptide-specific T lymphocytes were induced by immuni-
zation of LEW rats with a WF rat peptide. The subsequent in vitro culture, in which 
the lymphocytes were incubated for three days with peptide-bearing dendritic cells 
(DC), determined the proliferation induced by the second contact with this peptide. 
In addition to dendritic cells, other MHC-class-II expressing cells such as B lympho-
cytes and macrophages can also present synthetic allo-MHC-peptides. 8 
 
 
 
3.1 IMMUNOMODULATION WITH ALLO-MHC-PEPTIDES  
Various studies have shown that under certain circumstances allo-MHC-peptides can 
inhibit or at least delay graft rejection [95, 96, 97, 98]. Their oral application in 
particular is a highly attractive possibility, even though the mechanism of oral 
tolerance [99] is not yet sufficiently understood for its successful application in 
                                       
8 Timmermann W, Sitaru G, Kottenmeier S, Gassel HJ, Ulrichs K, Otto C. Alloantigen specific 
modulation of the immune response after transplantation using immunodominant peptides. 
Deutsche Gesellschaft für Chirurgie, Forumband 2003 32: 341-343 
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clinical practice [100, 101]. It is the contrasting properties of allo-MHC-peptides to 
act in both an immunostimulatory and immunomodulating manner that makes them 
especially attractive. They could help to ascertain which factors determine whether 
exposure to antigens induces T lymphocytes to trigger or suppress an immune 
response directed against the graft.  
 
The basis for the experiments described in publication 1 9 is the long known but 
not yet fully understood finding that a pretransplantation blood transfusion from 
donor to recipient has a beneficial effect on later graft function [102]. This strategy, 
termed transfusion associated immunosuppression (TRIM), was first described by 
Opelz [103]. Although it lost some of it importance with the introduction of CsA 
(Chapter 2.2) [104], there is no doubt that such a blood transfusion benefits graft 
survival [105]. On the other hand, such a donor-specific blood transfusion can also 
lead to a sensitization of the recipient that accelerates graft rejection [106]. The 
same effect is produced by allo-MHC-peptides, suggesting they constitute the 
therapeutically active component of TRIM [107]. 
 
Based on these observations we carried out the following experiments with the two 
immunogenic MHC-class-II peptides RT1.B2 and RT1.D2. As shown in Fig. 3.2 for 
MHC-class-I peptides, these peptides derived from the RT1u haplotype represent the 
allogeneic dominants compared to the RT1l haplotype (the haplotype of LEW rat) 
peptides. They activate alloreactive CD4+ T lymphocytes, which in turn induced 
rejection of vascularized RT1u grafts in LEW rats. Their possible protective activity on 
graft function was investigated in two combined approaches, each involving one of 
the two immunogenic allo-MHC-class-II-peptides and the calcineurin inhibitor CsA. 
CsA was applied to suppress the activated T lymphocytes. If the recipient animals 
were sensitized 7 day prior to transplantation with peptide RT1.B2 and treated up to 
post-transplant day 30 with low-dose CsA, the result was a clear prolongation of 
graft function. No reactive RT1.B2-specific CD4+ T lymphocytes could be 
                                       
9 Otto C, Gasser M, Waaga-Gasser AM, Rohde AC, Lenhard M, Jost S, Gassel HJ, Ulrichs K, 
Timmermann W. Prolongation of small bowel allograft survival with a sequential therapy 
consisting of a synthetic MHC class II peptide and temporarily low-dose cyclosporine A. Human 
Immunol 2002; 63: 880-887 
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demonstrated in the RT1.B2-immunized animals. This appears to explain the success 
of the RT1.B2 combination therapy. The regulator T lymphocytes are the basis of this 
phenomenon, which is known as "linked suppression" or "linked unresponsiveness" 
[108, 109]. It is not yet known, however, which allo-MHC-peptides are suitable for 
protective immunomodulation and which not.10 
 
Since the alloimmune response does not appear to be limited to single allo-MHC-
peptide antigens, the first step toward a peptide-based immunotherapy needs to 
explain how to identify candidates suitable for immunomodulation. The goal of 
publication 2 11 therefore was to determine which allo-MHC-class-I-peptide antigens 
dominate in the alloimmune response, so as then to use them for modification of 
their amino acid sequence (Tab. 3.1). For this purpose seven different RT1u peptides 
were tested for their alloreactivity in LEW rats. These MHC-class-I-peptides represent 
the areas in the RT1u haplotype that differ from the RT1l haplotype, i.e. the amino 
acids found in this area must be those responsible for the alloreactivity (Fig. 3.2).  
 
Of the seven investigated peptides P1 to P7, immunization with P1 12 produced the 
strongest activation. Whereas P1 is by virtue of the strength of the T-cell 
proliferation it induces the immunodominant peptide, the other six peptides are only 
slightly (P2-P5) or not at all (P6, P7) immunogenic.  
 
An important question for transplantation immunologists is whether synthetic allo-
MHC-peptides, such as the allo-MHC-class-I-peptide P1 also promote the rejection of 
vascularized organ transplants. Experiments have been preformed to investigate 
their effect on graft function in a heterotopic heart transplantation model [110] with 
LEW rats as recipients, WF rats as donors. Immunization with P1 was found to 
reduce transplant function time in the LEW rats to 4.5 ± 0.5 days versus the 8 days 
                                       
10 Otto C, Rohde AC, Timmermann W, Waaga AM, Gebert A, Gasser M, Gassel HJ, Thiede A, Ulrichs 
K. Acceptance of small bowel allografts by indirect allorecognition of donor MHC class II 
allopeptides. Transplant Proc 2001; 33: 431-432 
11 Sitaru AG, Timmermann W, Ulrichs K, Otto C. Hierachical immunogenicity of donor MHC class I 
peptides in allotransplantation. Human Immunol 2002; 63: 871-879 
12 Sitaru AG, Timmermann W, Ulrichs K, Otto C. Modulation of the T cell response with an MHC class 
I immunodominant peptide and its analogues. Immunobiol 2001; 204: 209 (abstract) 
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in nonimmunized rats. In addition, transfer of P1-specific T lymphocytes to LEW rats 
reduced the transplant function time of heterotopic heart transplants to 5.3 ± 0.5 
days. A peptide that is not immunogenic in proliferation assays (Fig. 3.3) also does 
not affect the time of rejection. 
 
The presentation of allo-MHC-peptides by MHC class-II molecules is a key event in 
the indirect T-cell response against alloantigens of the transplant. The 
characterization of these synthetic allo-MHC-class-I peptide antigens supports the 
view that their allogenicity exhibits a hierarchical distribution [111], a phenomenon 
also observed in clinical practice [112, 113]. This means that the alloreactive T 
lymphocytes do not recognize all antigen determinants identified by sequence 
comparison. This important observation appears to diminish the number of MHC 
peptide antigens to a few candidate peptides and supports the optimism regarding 
the development of an antigen specific immunotherapy. When these peptides are 
tested in another rat strain the distribution of the alloreactivity also changes. This 
shows that any possible antigen-specific immunotherapy must be tailored to the 
particular donor-recipient combination.  
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3.2 IMMUNOMODULATION WITH ALLO-MHC-PEPTIDE VARIANTS 13 
Our goal is to suppress the activation and proliferation of alloreactive T lymphocytes 
using variants made from the immunodominant allo-MHC peptide antigens. It would 
be extremely attractive to modulate certain effector functions, such as the production 
of interleukins, in such a manner that these cells become active as regulators. We 
investigated the effect different variants derived from the immunodominant peptide 
P1 had on the activation of alloreactive T lymphocytes and graft function. For this 
purpose the three divergent amino acids in the MHC-class-I molecules WF rat were 
sequentially replaced by those located at the same position in the MHC-class-I 
molecules of LEW rat (Table 3.1).  
 
Table 3.1. PRODUCTION OF ALLO-MHC-CLASS-I-PEPTIDE VARIANTS. The variants 
A1.1 to A1.6 are derived from peptide P1, which is identical to the corresponding 
sequence of the RT1u haplotype (cf. also Fig. 3.2). In the first 19 amino acids the 
two haplotypes RT1u and RT1l differ at positions 5, 9 and 10. The six P1 variants 
originate from sequential amino acid exchanges between the two haplotypes 
(unpublished data). Positions 5, 9 and 10 represent, since they are the only 
differences between the RT1u and RT1l haplotype in this area in MHC-class-I 
molecule, the recognition or core sequence for P1-specific T lymphocytes. 
 
Peptide Amino acid Sequence 
  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
 RT1Au G S H S L R Y F L T A V S R P G L G E
 P1 G S H S L R Y F L T A V S R P G L G E
 A1.1 - - - - M - - - L T - - - - - - - - - 
 A1.2 - - - - L - - - D T - - - - - - - - - 
 A1.3 - - - - L - - - L I - - - - - - - - - 
 A1.4 - - - - M - - - D T - - - - - - - - - 
 A1.5 - - - - L -  - D I - - - - - - - - - 
 A1.6 - - - - M - - - L I - - - - - - - - - 
 RT1Al G S H S M R Y F D I A V S R P G L G E
 
 
 
                                       
13 Sitaru AG, Timmermann W, Ulrichs K, Otto C. Allogeneic core amino acids of immunodominant 
allopeptide are important for MHC binding and TCR recognition. Human Immunol 2004; 65: 
817-825 
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Our results show that with the exception of A1.5 all P1 variants of P1-specific T 
lymphocytes were recognized. The slight immunogenicity of A1.5 for P1-specific T 
lymphocytes was also confirmed in the transplantation model (Fig. 3.4). The 
"normal" rejection time for this strain combination was 8 days. The same time point 
was also observed after sensitization with the A1.5 variant. If the recipient was 
immunized subcutaneously with a combination of A1.5 and P1 at the same molar 
concentrations prior to transplantation, the sensitization effect of P1 was not 
observed and the transplant was rejected on day 8. But if P1 and A1.5 were applied 
separately, then A1.5 had no protective effect and the graft was rejected on day 5, 
the same as after immunization with P1 (Fig. 3.4). 
 
 
 
FIGURE 3.4: THE IN VIVO 
EFFECT OF A1.5 ON 
TRANSPLANT FUNCTION. The 
P1 peptide variant A1.5 
delays the immunodominant 
peptide P1-induced accelera-
ted transplant rejection when 
it is applied together with the 
P1 peptide (P1 + A1.5), but 
not when the two peptides 
are applied separately [(P1) + (A1.5)]. The results are shown as mean ± standard 
deviation of n = 4 animals. 
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FIGURE 3.5: PRINCIPLE AND RESULTS OF THE MHC-INHIBITION ASSAY. The measured 
proliferation of the P1-specific cells shows whether the P1 peptide continues to be 
reside within the binding groove formed by the MHC-class-II-proteins or has been 
displaced by the A1.5 variant. The results indicate that the A1.5 variant did indeed 
displace the P1 antigens. Since A1.5 is a suboptimal antigen for P1-specific T-
Lymphocytes, this results in diminished proliferation. The control peptide Ac (a 
peptide representing and area of the MHC-class-I molecule in which both haplotypes 
are identical) does not possess this property. 
 
 
 
The exchange of individual amino acids in immunogenic peptides can influence both 
recognition via the T-cell receptor and binding to the MHC-class-II molecule. We 
investigated whether the A1.5 variant can displace already bound P1-peptides from 
the MHC-class-II-binding groove. For this purpose APC were first loaded with the 
immunodominant peptide P1 and then incubated with the A1.5 peptide variant at the 
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same molar concentration. Should A1.5 exhibit greater binding affinity for the RT1l 
MHC-class-II-molecule, then P1 will be displaced from the binding groove and the 
subsequent incubation with P1-specific T lymphocytes lead to diminished prolife-
ration. The results of the MHC-inhibition assay support this interpretation 
(Fig. 3.5).14, 15 
 
In the indirect pathway of alloantigen recognition a highly diverse array of allo-MHC-
peptides with defined allogeneic determinants are presented to the alloreactive 
CD4+ T lymphocytes. This pathway is therefore especially well-suited for the 
introducing altered synthetic peptides into the immune system. Whereas the 
identification of immunodominant allo-MHC-peptides is already possible for certain 
donor–recipient combinations, variants with immunomodulating properties can not 
yet be produced. The molecular knowledge for ascertaining whether allo-MHC-
peptides possess immunomodulating and/or immunoactivating properties, a 
prerequisite for clinically feasible development of such procedures, is still lacking 
[114, 115]. It must especially be determined whether the immunomodulating 
properties have a definite structural pattern in these peptides. Knowledge of the 
structure of the T-cell receptors of tolerogenic T lymphocytes could be of help in 
recognizing such tolerogenic peptide structures, i.e. knowledge as to which amino 
acids must be located at which positions in the peptide so that interaction with the 
tolerogenic T-cell receptor can occur. This knowledge can be used to direct the 
computer-aided search for similar structures in peptide databanks. The procedure 
presented here (Tab. 3.1) for production of variants could be an alternative. 
                                       
14 Otto C, Sitaru G, Ulrichs K, Timmermann W. Design of peptide analogues as a strategy to modulate 
the alloresponse of peptide-specific T cells. Transplantation [Suppl] 2002; 74: 271 (abstract) 
15 Sitaru G, Timmermann W, Ulrichs K, Otto C. Immunodominant peptide analogues as a strategy to 
modulate the alloimmune response. Immunobiol 2002; 206: 283 (abstract) 
  25
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.6: IMMUNOMODULATING PEPTIDE VARIANTS AS THE BASIS FOR THE IDEAL 
THERAPY FOR ANTIGEN-SPECIFIC SUPPRESSION OF TRANSPLANT REJECTION. The 
problem will not be the large-scale production of such variants, using e.g. "phage 
display" banks, but their biological testing with "high-throughput-screening". The 
alternative would be to test only a few highly promising candidates in the assay 
presented here (Fig. 3.3). A cell of the graft with alloantigens (either allo-MHC-class-I 
or class-II-molecules) is shown in red. 
 
 
 
3.4 IMMUNOMODULATION WITH REGULATORY CD4+ T LYMPHOCYTES 
Among the possible mediators of peripheral tolerance, regulatory T lymphocytes 
stand at the center of interest. It is conceivable that regulatory T lymphocytes 
generated in vivo or in vitro could be used to suppress graft rejection.  
 
Two major problems currently occupy transplantation immunologists: One is the 
difficulty of successfully applying the tolerance-inducing concept in clinical practice, 
the other is the difficulty of establishing systems to reliably test for tolerance. At 
present no or only scant information is available on whether liver transplant 
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♦ Microchimerism / passenger leukocytes
♦ Apoptosis of alloreactive T lymphocytes
♦ Soluble MHC class-I molecules
♦ Regulatory T cells
TOLERANCE
recipients can discontinue immunosuppression when graft tolerance has become 
established in them. No physician would dare stop immunosuppression or reduce 
doses without definite indications of stable tolerance. The main criterion at present 
for selecting patients for dosage reduction is the time of rejection-free episodes 
following transplantation (die Zeit rejectionsfreier Episoden nach Transplantation) 
[116, 117]. It is uncertain however whether this is sufficient as a selection criterion. 
A reliable marker of tolerance would represent a giant step forward. It is also unclear 
just what would form such a marker would take, whether it would be a certain cell 
population, a certain interleukin pattern, an intracellular component such as an 
enzyme in the signal chain, or a 
transcription factor. It is in this 
context, i.e. the search for a marker 
of tolerance, that the following 
experiments are to be regarded.  
 
 
 
FIGURE 3.7: SURVEY OF THE POSSIBLE 
MECHANISMS OF SPONTANEOUS 
TOLERANCE OF LIVER TRANSPLANTS 
[118, 119, 120].  
 
 
 
3.4.1 IMMUNOBIOLOGICAL PROPERTIES OF LIVER TRANSPLANTS  
The investigations in publication 3 16 focused on whether in immunosuppressive 
combination therapies monoclonal antibodies can compensate for the diminished 
immunosuppressive potency brought on by the reduction of dosage. Such studies are 
important insofar as they underpin our working hypothesis that certain hepatic cell 
                                       
16 Gassel HJ, Otto C, Gassel AM, Meyer D, Steger U, Timmermann W, Ulrichs K, Thiede A. Tolerance 
of rat liver allografts induced by short-term selective immunosuppression combining monoclonal 
antibodies directed against CD25 and CD54 with subtherapeutic cyclosporine. Transplantation 
2000; 69: 1058-1067 
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populations may be associated with the tolerance of liver transplants.17 These data 
are also highly interesting since combination therapy with CsA and the two 
antibodies NDS-61 (blockade of the IL-2 receptor) and 1A29 (blockade of cell-cell 
interaction) induces long-term acceptance of liver grafts based on antigen-specific 
tolerance. All of the agents in this selective immunosuppression were applied at 
minimal effective doses [121]. The blockade of cell adhesion by 1A29 hampers the 
interaction between the alloreactive T lymphocytes and the APC. CsA suppresses the 
transcription of IL-2 mRNA in activated T lymphocytes, whereas NDS-61 blocks the 
formation of IL-2 on the IL-2 receptor. This immunosuppressive protocol thus acts 
mainly in the early phase of T-cell activation. The extent to which this protocol 
contributes to the propagation of regulatory T lymphocytes can only speculated on at 
this time. It is known that in order to survive CD25+ regulatory T lymphocytes 
require -- in addition to the T-cell receptor-mediated signal -- exogenous IL-2 (page 
15). The CD25+ cells are, as we and others have shown, also a component of the 
lymph node population in rat.18 
 
Publication 4 19 presents the hepatic lymphocyte population in tolerated liver 
transplants. The immunobiological properties of hepatic leukocytes, especially the T 
lymphocytes, appear to differ markedly from those of leukocytes in other organs. 
The liver possesses, for example, dendritic cells and a very large macrophage 
population. The necessity of not inducing an immune response to the harmless 
constituents of nutrients explains why the local presentation of antigens usually does 
not lead to the propagation of activated T lymphocytes. The survival of activated T 
lymphocytes is limited by both "activation-induced cell death" and "death by neglect" 
[122]. The acceptance and tolerance of liver transplants are attributed in part to 
                                       
17 Otto C, Gassel H-J. Look insight: Die Leber als immunologisches Organ. Z Gastroenterol 2002; 40: 
468 (abstract) 
18 Otto C, Kuckein O, Ulrichs K. Characterization of rat CD4+ CD25+ T regulator cells. Immunobiol 
2003; 208: 254 
19 Gassel HJ, Otto C, Klein I, Steger U, Meyer D, Gassel AM, Ulrichs K, Thiede A. Persistence of stable 
intragraft cell chimerism in rat liver allografts after drug-induced tolerance. Transplantation 
2001; 71: 1848-1852 
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such effects [123].20  Studies on local cytokine patterns also point to the presence of 
regulatory T lymphocytes [124]. 
 
A further discovery of recent years is that dendritic cells, which were originally regarded 
as potent activators of an adaptive immune response, are also effective inhibitors of an 
immune response [125] via interleukins or cell-cell-contacts [126]. Hepatic DC also 
possess tolerogenic properties [127]. Some hepatic subpopulations are characterized by 
a reduced expression of costimulatory molecules [128]. We could thus show that 
tolerated liver transplants possess hepatic dendritic cells with diminished expression of 
the costimulatory molecules CD80 and CD86.21 Publication 5 22 describes the long-
term presence of intrahepatic DC in tolerated liver transplants.  
 
 
3.4.2 DEMONSTRATION OF HEPATIC CD45RCneg T LYMPHOCYTES 
Publication 6 23 investigates whether in certain situations after transplantation the 
formation of Th2 cells, including possibly regulatory T lymphocytes, is promoted 
[129]. Our own data on possible tolerance-inducing hepatic populations (publications 
3 to 5) suggest that the alloimmune response especially in the liver transplant leads 
to the formation of regulatory T lymphocytes.24  
 
CD4+ T lymphocytes can be further differentiated according to their expression of 
certain isotypes of the CD45-molecules ("leukocyte common antigen") [130]. In rat 
the OX22 antibody is a marker of the high molecular-weight isoform of CD45RC 
                                       
20 Gassel HJ, Otto C, Klein I, Meyer D, Timmermann W, Ulrichs K, Thiede A. Analysis of cellular 
events in hepatic allografts: Donor progenitors induced intragraft chimerism. Transpl Int 2000; 
13 [Suppl 1]: 465-470 
21 Otto C, Öhrlein E, Meyer D, Timmermann W, Gassel HJ, Thiede A, Ulrichs K. Detection of dendritic 
cells with downregulated CD80/CD86, but normal MHC class II expression after rat liver 
transplantation. Transplant Proc 2001; 33: 442-444 
22 Meyer D, Löffeler S, Otto C, Czub S, Gassel HJ, Timmermann W, Thiede A, Ulrichs K. Donor-derived 
alloantigen-presenting cells persist in the liver allograft during tolerance induction. Transplant 
Int 2000; 13: 12-20 
23 Otto C, Kauczoc J, Martens M, Steger U, Möller I, Meyer D, Timmermann W, Ulrichs K, Gassel HJ. 
Mechanisms of tolerance induction after rat liver transplantation: Intrahepatic CD4+ T cells 
produce different cytokines during rejection and tolerance in response to stimulation. J 
Gastrointest Surg 2002; 6: 455-463 
24 Gassel HJ, Otto C. Mechanismen der Immuntoleranz nach orthotoper Lebertransplantation. 
Transplant Links 2002; 2: 49-58 
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[131]. Two distinct CD4+ subpopulations are distinguished: CD45RCpos cells, which 
represent the naïve phenotype, and CD45RCneg cells. These are activated cells or so-
called "memory cells". When stimulated the CD4+ CD45RCpos T lymphocytes produce 
more IL-2 and IFN-γ than IL-4, the CD4+ CD45RCneg T lymphocytes more IL-4 than 
IL-2 and IFN-γ [132, 133].  
 
The CD4+ CD45RCneg T lymphocytes in particular appear to have immunoregulatory 
properties, some data indicating that the organs from which they are isolated also 
have an influence on the properties of these cells. Thus CD45RCneg T lymphocytes 
isolated from spontaneously tolerated liver transplants differ from those isolated from 
the spleen of the same animal. When activated in vitro CD4+ CD45RCneg T 
lymphocytes isolated from tolerated liver transplants produce the immunoregulatory 
interleukin IL-13 at both the mRNA and protein level25. IL-13 production could be 
demonstrated from day 30 to day 100 after transplantation, when the study ended. 
This property is not possessed by the other hepatic CD4+ subpopulation with the 
CD45RCpos phenotype as well as CD4+ CD45RCneg T lymphocytes of the spleen.26  
 
It is not known whether the Th2 interleukin IL-13 performs an immunomodulating 
function within the liver by suppressing macrophage-induced inflammatory processes 
[134]. IL-13 could also be the sought after marker for both hepatic regulatory T 
lymphocytes and stable transplant tolerance. It remains for future studies to 
elucidate the regulatory function of these cells. 
                                       
25 Gassel HJ, Kauczok J, Martens N, Steger U, Timmermann W, Ulrichs K, Otto C. Tolerance induction 
following orthotopic rat liver transplantation: Cytokine production by CD4+ T cells determines 
the immunological response. Transplant Proc 2002; 34: 1429-1430 
26 Otto C, Schmitz P et al. Publication in preparation 
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The liver’s unique ability to down regulate local immune responses could also be 
used to more effectively induce the so-called "linked unresponsiveness" mediated by 
allo-MHC-peptides and their variants. One possibility is the targeted vesicle-mediated 
transport of these peptides into the liver. Or the genetic information of these allo-
MHC peptides could be permanently or temporarily introduced into and subsequently 
expressed by the hepatocytes (Fig. 3.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.8: STRATEGY FOR INCREASING THE MODULATION POTENTIAL OF MHC-CLASS-
I PEPTIDES OR THEIR VARIANTS BY APPLICATION IN THE LIVER. This approach may 
promote the formation of hepatic regulatory cells. It is based on the (still 
hypothetical) connection between allo-MHC-peptides and their potential to induce 
regulatory T lymphocytes as shown in Fig. 2.4. Moreover, these cells and/or the 
interleukin IL-13 they secrete could serve as biological markers of an altered 
immunological situation and thus as the sought after marker of tolerance. The allo-
MHC-class-I-peptides and/or their variants are shown in red. 
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4.  PR O S P E C T S/OU T L O O K 
The two experimental approaches for modulation of the immune system with allo-
MHC-peptide variants and regulatory CD4+ T lymphocytes presented here are 
clinically best suited for living donations (kidney or partial liver donation). Due to the 
stagnating number of brain-dead organ donors, living donations represent an 
increasingly important alternative. Since the operation can be planned in advance, 
there should be sufficient time to carry out the necessary examinations and analyses 
needed for an immunomodulating strategy. Even if the five-year survival rate for 
kidney transplants from living donors is very high at 80%, the expenses an 
immunomodulating procedure entails is certainly justified if it brings one closer to the 
long-term goal of 100% transplant function.  
 
Although both ideal therapy concepts presented here, immunomodulation with allo-
MHC-peptide variants and regulatory CD4+ T lymphocytes, are still in the 
experimental phase, strategies for their clinical application can already be planned 
(Fig. 4.1). Whereas the immune response induced by the direct pathway of 
alloantigen recognition can be inhibited by short-term immunosuppression, the 
indirect pathway of alloantigen recognition allows Immunomodulative approaches 
using allo-MHC peptide variants. It is conceivable that these peptides can be used to 
inhibit the immune response, modulate T-cell activation, or -- and this would be and 
extremely attractive strategy -- induce the formation of regulator cells. The success 
of such a therapy depends in part on the extent to which the phenomenon of 
"epitope spreading", that is the expansion of the epitope repertoire, can be 
controlled in the late phase after transplantation. In the early phase, the alloimmune 
response is limited to a few dominant epitopes, whereas in the late phase further 
antigens are involved that can be recognized by alloreactive T lymphocytes [135, 
136].  
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FIGURE 4.1: POSSIBLE CLINICAL APPLICATIONS OF THE IDEAL THERAPY. This procedure 
would use a combination of short-term conventional immunosuppression and an 
antigen-specific immunotherapy. The organ transplant and the passenger leukocytes 
are shown in red, the immune cells of the host in gray. 
 
 
 
The antigen-specific modulation of the T-cell response after transplantation probably 
also promotes the cellular and molecular mechanisms leading to tolerance, in order 
to also clinically realize the ultimate goal of transplantation research, the induction of 
transplant-specific tolerance. That this continues to be of undiminished relevance is 
underscored by the founding of the international Immune Tolerance Network for 
initiating and coordinating promising clinical studies on tolerance induction as well as 
on validating test systems for confirming tolerance [137]. Here, molecular-
immunological markers for reliable demonstration of tolerance are of supreme 
important. The currently available in vitro assays are not always capable of 
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demonstrating the phase of stable tolerance [138, 139, 140]. One reason for this is 
that the underlying mechanisms that determine when an activated T lymphocyte 
becomes alloreactive or tolerant are not fully understood. This then is a basic 
prerequisite for successful establishment of such assays. 
 
The phenomenon of clonal deletion is an extremely important mechanism for limiting 
the formation of autoreactive T lymphocytes [141, 142]. It is also essential for the 
induction of transplant-specific tolerance, although so-called active mechanisms are 
currently preferred, such as the presence of regulatory T lymphocytes [143]. This 
also means that an altered immunological situation (= tolerance) after 
transplantation could be demonstrated by the presence of such cells and/or of the 
interleukins they secrete. This new way of approaching the problem could contribute 
to the solving of one of the basic problems in transplantation, the lack of markers of 
tolerance. 
 
Recent data point to a genetic predisposition affecting whether or not a recipient 
rejects a transplant under immunosuppression [144]. The Human Genome Project 
could provide invaluable data for such predictions in particular, but also for the 
development of individualized immunosuppression. 
 
Transplantation is currently the only therapy for irreversibly damaged organs. 
Although its success is due mainly to the immunosuppression concept, the latter’s 
severe shortcomings demand the development of new strategies. The experimental 
approaches for antigen-specific immunomodulation presented here could form the 
basis for both an ideal therapy and new diagnostic concepts. 
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